Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
In Vitro Cell-Based Models of Drug-Induced Hepatotoxicity Screening: Progress and Limitation Publisher Pubmed



Mirahmad M1 ; Sabourian R2 ; Mahdavi M1 ; Larijani B1 ; Safavi M3
Authors

Source: Drug Metabolism Reviews Published:2022


Abstract

Drug-induced liver injury (DILI) is one of the major causes of post-approval withdrawal of therapeutics. As a result, there is an increasing need for accurate predictive in vitro assays that reliably detect hepatotoxic drug candidates while reducing drug discovery time, costs, and the number of animal experiments. In vitro hepatocyte-based research has led to an improved comprehension of the underlying mechanisms of chemical toxicity and can assist the prioritization of therapeutic choices with low hepatotoxicity risk. Therefore, several in vitro systems have been generated over the last few decades. This review aims to comprehensively present the development and validation of two-dimensional (2D) and three-dimensional (3D) culture approaches on hepatotoxicity screening of compounds and highlight the main factors affecting predictive power of experiments. To this end, we first summarize some of the recognized hepatotoxicity mechanisms and related assays used to appraise DILI mechanisms and then discuss the challenges and limitations of in vitro models. © 2022 Informa UK Limited, trading as Taylor & Francis Group.
1. Liver-On-A-Chip, Principles of Human Organs-on-Chips (2023)
2. Generation of Scalable Hepatic Micro-Tissues As a Platform for Toxicological Studies, Tissue Engineering and Regenerative Medicine (2020)
3. Hepatotoxicity Induced by Azole Antifungal Agents: A Review Study, Iranian Journal of Pharmaceutical Research (2023)
Experts (# of related papers)
Other Related Docs
5. Functional Liver Cell–Based Platforms in Biomedical Research, Pharmacology Research and Perspectives (2025)
7. Tumor Organoid As a Drug Screening Platform for Cancer Research, Current Stem Cell Research and Therapy (2024)
10. Advancement of Organoid Technology in Regenerative Medicine, Regenerative Engineering and Translational Medicine (2023)